Douglas Eby, founder and CEO of Kyttaro (Harvard)
Stealth UK biotech in-licenses Lilly candidates in pursuit of 'inhibiting the inhibitor' in cardiovascular disease
Just last April, biotech incubator Cambridge Science spun out a tiny biotech to focus solely on cardiovascular disease. A year later, it has acquired two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
